A FibroScan® Alternative for Point-of-Care Liver Stiffness Measurement

iLivTouch® is a transient elastography system that measures liver stiffness and steatosis at the point of care, used in GI, hepatology, endocrinology and primary care settings, with over 6,000 units installed worldwide.

iLivTouch® measures liver stiffness, reported in kPa, and steatosis (fat in the liver), reported as an attenuation value, supporting noninvasive assessment of liver fibrosis and fatty liver disease, including MASLD and MASH.

What iLivTouch® Measures

Both iLivTouch® and FibroScan® perform transient elastography to measure liver stiffness. iLivTouch adds real-time B-mode ultrasound imaging guidance, allowing the operator to visualize the liver and select the measurement site directly rather than measure blindly. It is offered in a portable model (Mini800) and a cart-based model (FT9000). Examinations with imaging guidance are billed under CPT 76981, while elastography without imaging guidance falls under CPT 91200.

iLivTouch® vs. FibroScan®: How They Compare

iLivTouch FT9000 Ultrasound machine with monitor and control panel on wheels

FT9000 Product Brochure

iLivTouch Mini800 with attached tool and interface displaying diagnostic data

Mini800 Product Brochure

Sample Report (B-Mode)

Report Interpretation Reference Chart

Reimbursement Guide

Operation Guide for Mini800

HISKY Medical Mini800 ultrasound probe (B-mode image) included for Vibration Controlled Transient Elastography - measures Fatty Liver (steatosis score) and Fibrosis score. The patient lies on an exam table while the operator uses real-time B-mode ultrasound imaging guidance to see the liver and select the measurement site. The exam takes a few minutes, is painless and noninvasive, and results are available immediately.

Reimbursement: CPT 76981

Liver elastography with imaging guidance is billed under CPT 76981. NexGen provides a reimbursement guide with code details and documentation guidance — request it with a demo and our team will walk through it with you.

Presented at the 2024 AASLD, this multicenter, prospective study conducted by NYU Langone Health, in collaboration with Baylor College of Medicine, demonstrated a strong correlation between iLivTouch and FibroScan in assessing liver stiffness and attenuation parameters. iLivTouch’s 2D image-guided function facilitated the identification of the optimal test spot. Both devices are effective for diagnosing and grading liver fibrosis and steatosis, and for composing FAST scores, without safety concerns.

A scientific research poster from The Liver Meeting discussing the correlation between measurements obtained by the iLivTouch and FibroScan devices in patients with liver fibrosis. The poster includes sections on introduction, aim, method, results with a table of baseline variables, conclusions, references, acknowledgements, and contact information.

Learn more

Trademark Notice: FibroScan® and VCTE® are registered trademarks of Echosens. iLivTouch and NexGen Therapeutics are not affiliated with, sponsored by, or endorsed by Echosens.

Clinical Evidence

Evaluating the Significance of Viscoelasticity in Diagnosing Early-Stage Liver Fibrosis with Transient Elastography

PLOS One

Diagnostic Value of Various Noninvasive Indexes in the Diagnosis of Chronic Hepatic Fibrosis

European Review for Medical and Pharmacological Sciences

Prediction of Posthepatectomy Liver Failure Using Transient Elastography in Patients with Hepatitis B Related Hepatocellular

BioMed Central Gastroenterology

Transient Elastography Identifies the Risk of Esophageal Varices and Bleeding in Patients With Hepatitis B Virus-Related Liver Cirrhosis

Ultrasound Quarterly

Prevalence of Liver Steatosis and Fibrosis in the General Population and Various High-Risk Populations: A Nationwide Study With 5.7 Million Adults in China

American Gastroenterological Association

Diagnostic Performance of FibroTouch Ultrasound Attenuation Parameter and Liver Stiffness Measurement in Assessing Hepatic Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

American College of Gastroenterology